151 related articles for article (PubMed ID: 33860650)
21. Elevation of serum pro-gastrin-releasing peptide in patients with medullary thyroid carcinoma and small cell lung carcinoma.
Ide A; Ashizawa K; Ishikawa N; Ishii R; Ando T; Abe Y; Sera N; Usa T; Tominaga T; Ejima E; Nakashima M; Ito K; Ito K; Eguchi K
Thyroid; 2001 Nov; 11(11):1055-61. PubMed ID: 11762716
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of chemiluminescent immunoassay quantitative detection for pro-gastrin-releasing peptide (ProGRP) in serum and plasma.
Cheng Y; He J; Zhang L; Chen X; Ou S
J Int Med Res; 2020 Apr; 48(4):300060519882802. PubMed ID: 31856626
[TBL] [Abstract][Full Text] [Related]
23. Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma.
Kratzsch J; Willenberg A; Frank-Raue K; Kempin U; Rocktäschel J; Raue F
Clin Chem Lab Med; 2021 Oct; 59(11):1861-1868. PubMed ID: 34256421
[TBL] [Abstract][Full Text] [Related]
24. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
Smith A; Galli M; Piga I; Denti V; Stella M; Chinello C; Fusco N; Leni D; Manzoni M; Roversi G; Garancini M; Pincelli AI; Cimino V; Capitoli G; Magni F; Pagni F
J Proteomics; 2019 Jan; 191():114-123. PubMed ID: 29581064
[TBL] [Abstract][Full Text] [Related]
25. Determining ProGRP and isoforms in lung and thyroid cancer patient samples: comparing an MS method with a routine clinical immunoassay.
Torsetnes SB; Broughton MN; Paus E; Halvorsen TG; Reubsaet L
Anal Bioanal Chem; 2014 Apr; 406(11):2733-8. PubMed ID: 24518900
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
27. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
[No Abstract] [Full Text] [Related]
28. Elevated basal serum levels of calcitonin and simultaneous surgery of MEN2A-specific tumors.
Tang HX; Yang H; Li F; Cao ZL; Huang YT; Qi XP
Neoplasma; 2021 Sep; 68(5):1098-1106. PubMed ID: 34156257
[TBL] [Abstract][Full Text] [Related]
29. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
Werner RA; Schmid JS; Muegge DO; Lückerath K; Higuchi T; Hänscheid H; Grelle I; Reiners C; Herrmann K; Buck AK; Lapa C
Medicine (Baltimore); 2015 Nov; 94(45):e2016. PubMed ID: 26559299
[TBL] [Abstract][Full Text] [Related]
31. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma.
Bojunga J; Dragan C; Schumm-Draeger PM; Usadel KH; Kusterer K
Br J Cancer; 2001 Nov; 85(10):1546-50. PubMed ID: 11720443
[TBL] [Abstract][Full Text] [Related]
32. Brain metastasis from calcitonin-negative medullary thyroid carcinoma.
Baptista PF; Fonseca LCM; Carvalho AFC; Silva SNVD; Freitas CRO
Ann Endocrinol (Paris); 2022 Aug; 83(4):258-260. PubMed ID: 35537523
[TBL] [Abstract][Full Text] [Related]
33. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma.
Algeciras-Schimnich A; Preissner CM; Theobald JP; Finseth MS; Grebe SK
J Clin Endocrinol Metab; 2009 Mar; 94(3):861-8. PubMed ID: 19088163
[TBL] [Abstract][Full Text] [Related]
34. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
Elisei R; Lorusso L; Piaggi P; Torregrossa L; Pellegrini G; Molinaro E; Agate L; Bottici V; Pani F; Cacciato Insilla A; Casella F; Ciampi R; Tognetti I; Materazzi G; Basolo F; Romei C
Eur J Endocrinol; 2015 Sep; 173(3):297-304. PubMed ID: 26034076
[TBL] [Abstract][Full Text] [Related]
35. Detection of CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and Their Relationship with CT Signs.
Tian K; Li Z; Qin L
Biomed Res Int; 2022; 2022():4119912. PubMed ID: 35937401
[TBL] [Abstract][Full Text] [Related]
36. Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma.
Nagakawa O; Furuya Y; Fujiuchi Y; Fuse H
Urology; 2002 Sep; 60(3):527-30. PubMed ID: 12350511
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
[TBL] [Abstract][Full Text] [Related]
38. [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].
Gao J; Zhang L; Peng K; Sun H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):886-891. PubMed ID: 35790439
[TBL] [Abstract][Full Text] [Related]
39. Immunoreactive gastrin-releasing peptide in medullary thyroid carcinoma.
Modigliani E; Casanova S; Chayvialle JA; Bernard C; Franc B; Cohen R; Calmettes C
J Clin Endocrinol Metab; 1990 Oct; 71(4):831-5. PubMed ID: 1976126
[TBL] [Abstract][Full Text] [Related]
40. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.
Fanget F; Demarchi MS; Maillard L; Lintis A; Decaussin M; Lifante JC
Br J Surg; 2021 Sep; 108(9):1064-1071. PubMed ID: 33899100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
